Brief: Artelo Biosciences Receives Favorable Uk Mhra Guidance For A Phase 1 Trial Of Art12.11, The Company’S Proprietary CbdTmp Cocrystal Being Developed For The Treatment Of Anxiety And Depression
01/08/2025 14:15
Artelo Biosciences Inc ARTL.O: ARTELO BIOSCIENCES RECEIVES FAVORABLE UK MHRA GUIDANCE FOR A PHASE 1 TRIAL OF ART12.11, THE COMPANY’S PROPRIETARY CBD:TMP COCRYSTAL BEING DEVELOPED FOR THE TREATMENT OF ANXIETY AND DEPRESSION ARTELO BIOSCIENCES INC - UK REGULATORY ASSURANCE EXPECTED TO REDUCE EXPENSES FOR ART12.11 Source text: ID:nGNX37jwf8 Further company coverage: ARTL.O